Rebio Health has been selected for Plug and Play Medtech (Batch 5, Warsaw, Indiana, USA)!

We are pleased to announce that Rebio Health has been selected for the “Warsaw Medtech Accelerator Program (Batch 5),” organized by the global innovation platform Plug and Play Tech Center, as the first Japanese startup to join the program.

🔗 Plug and Play’s official press release: https://www.plugandplaytechcenter.com/press/warsaw-medtech-batch-5

Through this selection, we will further accelerate the global development and commercialization of our electrochemical biofilm removal technology.

■ Our Technology: Electrochemical Biofilm Removal

Rebio Health is developing a novel technology that enables the disruption and removal of biofilms—structured communities of bacteria that are highly resistant to antibiotics and conventional cleaning methods—using an electrochemical approach.

This technology has potential applications in:

• Orthopedic implant-associated infections (e.g., joint replacements)

• Chronic wound infections

• Biofilms formed on medical device surfaces

It is expected to provide a low-invasive infection control solution with a novel mechanism of action, addressing one of the most persistent challenges in modern medicine.

■ About the Warsaw Medtech Program

The Warsaw Medtech Program is a global accelerator focused on medical devices, held in Warsaw, Indiana, USA. The region is widely known as the “Orthopedic Capital of the World” and has developed into a major hub for the orthopedic medical device industry.

The program operates within a strong ecosystem involving global medical device companies such as Zimmer Biomet, as well as leading healthcare providers including Parkview Health.

Through the Plug and Play Medtech program, selected startups gain access to:

• Collaboration opportunities with healthcare institutions and industry partners

• Mentorship from domain experts

• Business development and regulatory support

• Access to a global investor network

Startups are carefully selected from around the world, making it a highly competitive program.

■ Significance of the Selection

This selection demonstrates that the uniqueness and clinical relevance of our electrochemical biofilm control technology have been recognized at a global level.

In particular, within an ecosystem where leading medical device companies such as Zimmer Biomet closely collaborate with healthcare institutions, we expect to significantly accelerate the clinical validation and commercialization of our technology.

■ Future Outlook

Through participation in this program, Rebio Health will focus on:

• Accelerating the clinical application of our electrochemical biofilm removal technology

• Establishing collaborations and partnerships with healthcare institutions and industry players

• Expanding into the U.S. market

• Advancing fundraising efforts through engagement with global investors

  
  

In addition, we plan to participate in the final Expo, where we will present our progress to investors, corporate partners, and industry leaders.